cl 387785 has been researched along with canertinib dihydrochloride in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Althaus, IW; Amato, DM; Bridges, AJ; Denny, WA; Elliott, WL; Ellis, PA; Fry, DW; Gonzales, AJ; Han, HK; Harvey, PJ; Klutchko, SR; Meade, MA; Nelson, JM; Pace, G; Roberts, BJ; Sherwood, V; Showalter, HD; Smaill, JB; Tran, TP; Winters, RT; Zhou, H | 1 |
1 other study(ies) available for cl 387785 and canertinib dihydrochloride
Article | Year |
---|---|
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
Topics: Alkynes; Amides; Aniline Compounds; Animals; Antineoplastic Agents; Cell Line; Dogs; ErbB Receptors; Haplorhini; Humans; Mice; Mice, Nude; Mice, SCID; Phosphorylation; Pyrimidines; Quinazolines; Rats; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-4; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2006 |